Merck & Co., Inc. news

   Watch this stock
Showing stories 1 - 10 of about 170   

Articles published

MRK 55.19 +0.24 (0.44%)
price chart
Merck & Company, Inc. (NYSE:MRK) Price Target Update
Merck & Company, Inc. (NYSE:MRK): 11 Brokerage firm Analysts have agreed with the mean estimate for the short term price target of $66.36 in Merck & Company, Inc. (NYSE:MRK). However, the stock price could fluctuate by $ 3.17 from the estimate as it is ...
News Recap - Ford Motor Co. (NYSE:F) Merck & Co. Inc. (NYSE:MRK ...  wsnewspublishers
Large Outflow of Money Witnessed in Merck & Company, Inc.  Money Flow Index
Merck & Co., Inc. (NYSE:MRK) announced that the FDA has accepted its ...
Merck & Co., Inc. (NYSE:MRK) announced that the FDA has accepted its supplemental Biologics License Application (sBLA) for Keytruda, an anti-PD-1 therapy, for review.
Merck & Co Inc (NYSE:MRK) Declined on Trading Screens
[Business Wire] Merck & Co Inc (NYSE:MRK) (TREND ANALYSIS) asked that all customers, including patients, inspect all bottles of TEMODAR´┐Ż (temozolomide) capsules and all bottles of Temozolomide capsules (generic) for potential cracks in the ...
Merck andamp; Co., Inc. (MRK) Stock Update
Pharmaceutical giant Merck & Co., Inc.'s (NYSE:MRK) stock has performed modestly well this year, with some steep increases to offset the few declines.
Merck & Co. Inc. (NYSE:MRK) Skyrockets on FDA Green Signal against ...  StreetWise Report
Can Merck & Company, Inc. (NYSE:MRK) Surprise Analysts?
Merck & Company, Inc. (NYSE:MRK) is next slated to report earnings for the current quarter on 2015-10-27. Brokerages covering the stock are currently expecting the firm to earn $1 per share based on the 11 covering brokerages weighted into that average.
Merck & Co. Inc. (NYSE:MRK) Files Suit Against A Taiwan-Based Firm ...  StreetWise Report
Merck & Company, Inc. Short Interest Update  Money Flow Index
Why Merck andamp; Co., Inc. (MRK) Has Been Upgraded To An Outperform At BMO
Merck & Co., Inc. (NYSE:MRK) stock has been upgraded from a Market Perform to An Outperform at BMO Capital, by analysts Alex Arfaei and David Redfern via a report released August 13.
BMO Capital Markets Upgrades Merck & Co. Inc (NYSE:MRK) to " ...  OctaFinance.com
Good Data May Be Coming For Merck (And This Analyst Is Bullish)  Benzinga
Active Stocks in the News: Merck & Co., Inc (NYSE:MRK), SYSCO Corporation ...
Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection ...
Three Sinking Stocks: Hewlett-Packard Company (NYSE:HPQ), Merck & Co ...  Street Register
Zacks Short Term Rating on Merck & Company, Inc. (NYSE:MRK)
Analysts at Zacks have given a short term rating of hold on Merck & Company, Inc. (NYSE:MRK) with a rank of 3. The shares have received an average rating of 2 from 14 brokerage firms.
Novartis AG (ADR) Declines As Merck andamp; Co., Wins Patent Battle
Novartis AG ADR (NYSE:NVS) declined 2.3% during yesterday's trade as the company lost a patent battle to Merck & Co., Inc. (NYSE:MRK). The court ruled in favor of Merck, and restricted Sandoz, the generic unit of Novartis, from launching the generic ...
Verizon Communications Inc., Merck & Co., Inc. Get Stuck on the Sidelines
From a wider sentiment perspective, today's penchant for puts just echoes the withstanding trend seen in Merck & Co., Inc.'s options pits. For starters, the stock's 50-day ISE/CBOE/PHLX put/call volume ratio of 0.54 sits above 73% of all similar ...